The first generic formulations of the beta-blocker carvedilol (Coreg) have been approvedby the Food and Drug Administration for treating hypertension, mild to severe chronic heart failure, and left ventricular dysfunction following a myocardial infarction in clinically stable patients.
Available in four strengths—3.125 mg, 6.25 mg, 12.5 mg, and 25 mg—the tablets are made by these companies: Actavis Elizabeth LLC, Apotex Inc., Aurobindo Pharma Ltd., Caraco Pharmaceutical Laboratories Ltd., Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Mylan Pharmaceuticals Inc., Ranbaxy Laboratories Ltd., Sandoz Inc., Taro Pharmaceutical Industries Ltd., TEVA Pharmaceuticals USA, Watson Laboratories Inc., and Zydus Pharmaceuticals (USA) Inc.